news

Meveol vs Mycobacterium abscessus

Mon, 06/21/2010

Hypothiocyanite and Lactoferrin use for the treatment of Mycobacterium abscessus

Meveol vs Mycobacterium abscessus

Mon, 06/21/2010

Meveol use for the treatment of Mycobacterium abscessus

Effects of MEVEOL have been evaluated In Vitro on Mycobacterium abscessus (ATCC 19977 T)

Meveol : orphan drug status granted by the FDA for the treatment of cystic fibrosis.

Tue, 12/08/2009

Alaxia is glad to announce that its medicinal product candidate Hypothiocyanite (OSCN) / Lactoferrin developed under the brand name Meveol, received Orphan drug status for the treatment of cystic fibrosis (CF) by the US FDA (Food and Drug Administration).

Jean Paul Perraudin presents Meveol at Beijing, 9th Lactoferrin World Congress

Fri, 10/16/2009

Jean Paul Perraudin presents Meveol at Beijin 9th Intl Conference on Lactoferrin, Structure, Function &Applications 18-23rd Octobrer 2009 – Beijing, China.

Meveol is designated orphan medicinal product in Europe for the treatment of cystic fibrosis.

Wed, 09/02/2009

Alaxia announced that its drug candidate OSCN / Lactoferrin it develops under the brand name Meveol, was designated Orphan Medcicinal Product for the treatment of cystic fibrosis by the Commission of European Communities on positive opinion from the European Medicines Agency ( EMEA).